GALECTIN THERAPEUTICS INC. (NASDAQ:GALT) Files An 8-K Regulation FD Disclosure
Item7.01 Regulation FD Disclosure.
On March14, 2017, Galectin TherapeuticsInc. (the Company) issued
the press release attached hereto as Exhibit 99.1.Also, on
March14, 2017, Galectin TherapeuticsInc. posted on its website a
CEO Perspectives blog article entitled Galectin Inhibitor Therapy
Effective in Severe Atopic Dermatitis (Eczema), which is attached
as Exhibit 99.2.
The information in this report is being furnished to this
Item7.01 and shall not be deemed filed for purposes of Section18
of the Securities Exchange Act of 1934 (the Exchange Act) or
otherwise subject to the liabilities of that section, and it
shall not be deemed incorporated by reference in any filing under
the Securities Act of 1933 or under the Exchange Act, whether
made before or after the date hereof, except as expressly set
forth by specific reference in such filing to this report.
SECTION9 FINANCIAL STATEMENTS AND EXHIBITS
Item9.01 Financial Statements and Exhibits.
(d) Exhibits.
|
Exhibit Number |
Description |
|
| 99.1 | Press release | |
| 99.2 | CEO Perspectives |
– 2 –
About GALECTIN THERAPEUTICS INC. (NASDAQ:GALT)
Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer. The Company’s drug candidates are based on its method of targeting galectin proteins, which are mediators of biologic and pathologic functions. It uses naturally occurring, readily-available plant materials as starting material in manufacturing processes to create complex carbohydrates with specific molecular weights and other pharmaceutical properties. The Company has two product candidates, GR-MD-02 and GM-CT-01. The Company’s galectin-3 inhibitor is GR-MD-02. The Company is focusing on development of GR-MD-02 intended to be used in the treatment of liver fibrosis associated with fatty liver disease (NASH), moderate to severe plaque psoriasis and in cancer therapy in combination with immune-system modifying agent(s). GM-CT-01 is a compound that continues to be explored in preclinical studies. GALECTIN THERAPEUTICS INC. (NASDAQ:GALT) Recent Trading Information
GALECTIN THERAPEUTICS INC. (NASDAQ:GALT) closed its last trading session 00.00 at 1.81 with 555,741 shares trading hands.
